The FDA has accepted the supplemental new drug application for Zoryve cream 0.05% to treat mild to moderate atopic dermatitis ...

BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...

BioMarin Pharmaceutical BMRN reported fourth-quarter adjusted earnings per share of 92 cents, which beat the Zacks Consensus ...

Sanofi SA (NASDAQ:SNY) and Johnson & Johnson (NYSE:JNJ) have discontinued the E.mbrace phase 3 study evaluating a vaccine candidate for extraintestinal pathogenic E. coli. The E.mbrace study is a ...

Also Read: Sanofi Genzyme Facility Draws FDA Criticism Over Alleged Quality Lapses An independent data monitoring committee (IDMC) conducted a scheduled review of the E.mbrace phase 3 study.

Fitusiran (ALN-AT3) is a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT) in ...

Languages: English That has some policy experts confused about the FDA's ability to implement efficient recalls and protect Americans from foodborne illness or public health hazards. More ...

It can also range from mild to severe. Substance use disorder, formerly known as “drug abuse,” develops when substance use interferes with the ability to function day to day. Substance use ...